Danaher Corporation $DHR Shares Sold by OLD Second National Bank of Aurora

OLD Second National Bank of Aurora trimmed its position in shares of Danaher Corporation (NYSE:DHR) by 81.8% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,184 shares of the conglomerate’s stock after selling 9,831 shares during the period. OLD Second National Bank of Aurora’s holdings in Danaher were worth $484,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in DHR. Main Street Group LTD acquired a new stake in shares of Danaher in the first quarter valued at $25,000. N.E.W. Advisory Services LLC purchased a new stake in shares of Danaher in the 2nd quarter valued at $25,000. Marquette Asset Management LLC raised its holdings in shares of Danaher by 192.1% in the 3rd quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock valued at $25,000 after buying an additional 73 shares during the period. Evolution Wealth Management Inc. lifted its stake in Danaher by 208.0% during the 1st quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock worth $29,000 after acquiring an additional 104 shares in the last quarter. Finally, Field & Main Bank acquired a new position in Danaher during the 2nd quarter worth about $29,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, ahead of the $1.92 analyst consensus, while revenue increased 8.3% year over year to $6.55 billion. Biotechnology profitability and improving demand across several end markets supported the earnings beat. Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
• Positive Sentiment: Management raised its full-year 2026 adjusted EPS outlook to $8.57-$8.62, and biotechnology orders grew at a mid-teens rate. The company also highlighted margin expansion, improving customer demand, and artificial-intelligence capabilities that could support longer-term drug-discovery growth. Danaher: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Several analysts raised their price targets, including TD Cowen and JPMorgan to $270, Goldman Sachs to $275, and Stifel to $260. The upgrades reflect confidence in the earnings beat, improved execution, and the stronger profit outlook.
• Neutral Sentiment: New CEO Julie Montgomery emphasized the need to improve execution and innovation. Investors are watching whether management can convert the company’s AI and biotechnology investments into sustained growth. Danaher Posts First Earnings Under New CEO
• Negative Sentiment: Revenue was approximately in line with, or slightly below, estimates, while analysts cited tariff pressure and a cautious 2027 outlook. At roughly 41 times earnings, Danaher’s valuation leaves limited room for operational disappointment, contributing to the negative investor reaction despite the quarterly beat.

Danaher Stock Performance

Shares of DHR stock opened at $229.86 on Friday. The firm has a 50 day moving average of $215.76 and a two-hundred day moving average of $197.12. The stock has a market capitalization of $161.59 billion, a PE ratio of 40.83, a P/E/G ratio of 2.95 and a beta of 0.76. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.92 by $0.19. The business had revenue of $6.55 billion for the quarter, compared to analyst estimates of $6.56 billion. Danaher had a return on equity of 11.22% and a net margin of 16.91%. The company’s revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.89 earnings per share. On average, research analysts predict that Danaher Corporation will post 8.51 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s dividend payout ratio (DPR) is 28.42%.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of research analyst reports. The Goldman Sachs Group restated a “buy” rating and set a $275.00 target price on shares of Danaher in a report on Thursday. Citigroup lifted their target price on Danaher from $230.00 to $270.00 and gave the company a “buy” rating in a research report on Thursday. Stifel Nicolaus boosted their price target on shares of Danaher from $220.00 to $260.00 and gave the stock a “buy” rating in a research note on Thursday. Guggenheim increased their price target on shares of Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Finally, Wells Fargo & Company lowered their price objective on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $242.91.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.